Medicare Bridge Program Cuts GLP-1 Costs to $50
Eligible seniors can now get brand-name weight-loss GLP-1 drugs for $50 per month under the program.
Updated on Nov. 2, 2026 in Weight Loss
Live Poll
Should Medicare cover weight-loss GLP-1 drugs for seniors at a low monthly cost?
Prescribing of GLP-1 drugs among adults 65 and older rose nearly 21% between June and September 2026, following the July 1, 2026 launch of the Medicare GLP-1 Bridge program. Eligible beneficiaries pay $50 per month for brand-name Wegovy, Zepbound, or Foundayo for weight management.
Why it matters
The Bridge program gives older adults a lower-cost path to weight-management GLP-1 drugs that standard Medicare coverage currently does not provide. Because it operates outside Medicare Part D, it sidesteps the federal ban on Medicare covering weight-management drugs, and the Centers for Medicare & Medicaid Services (CMS) is using it to test whether broader coverage can work.
The figures come from CMS reporting on prescribing and sign-ups for the Bridge program, a federal demonstration rather than a controlled study. The source does not report a comparison-group analysis, so the 21% senior increase describes a change over time, not a measured drug effect.
The players
Centers for Medicare & Medicaid Services (CMS)
The federal agency that administers Medicare and Medicaid and oversees the Bridge program and the BALANCE pilot model.
Dr. Mehmet Oz
CMS Administrator who reported the roughly 600,000 Bridge program sign-ups by August 31, 2026.
The details
The Bridge program operates outside Medicare Part D, which lets CMS work around the federal rule that bars Medicare from covering drugs used for weight management. Eligibility is based on body mass index and certain health conditions, and beneficiaries pay a flat $50 per month. The program covers brand-name Wegovy, Zepbound, and Foundayo, and it was originally set to run six months before CMS extended it to 18 months.
Timeline
June 2026: baseline month used to measure the senior prescribing increase.
July 1, 2026: CMS launched the GLP-1 Bridge program.
August 31, 2026: the program reached about 600,000 sign-ups.
September 2026: end of the period in which the 21% senior increase was measured.
2027: the Bridge program is scheduled to end.
Health Landscape
The Bridge program is a workaround to the long-standing Part D exclusion of weight-management drugs, which is why it sits outside the standard benefit. The planned BALANCE model would integrate these medications into Part D and Medicaid, but the CMS canceled its Medicare portion after major payers declined to participate.
If you are an older adult weighing whether a GLP-1 medication fits your care plan, this program shows that lower-cost access is becoming available through Medicare. It is worth discussing with your doctor whether these medications are appropriate for you, given your body mass index and health conditions.
The takeaway
The sharp rise in senior prescribing shows how quickly cost barriers can shift behavior when coverage changes. Anyone considering a GLP-1 medication for weight management should ask their physician whether it fits their health profile and how the Bridge program's eligibility rules apply.
What happens next
The Bridge program is scheduled to end in 2027, and CMS plans to use its data to decide whether to reframe the BALANCE Model.
Further reading
For more on how these medications are being used, see our Weight Loss coverage.
Live Poll
Should Medicare cover weight-loss GLP-1 drugs for seniors at a low monthly cost?
